Related Experiment Videos
Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized
Mengyun Lei1, Qiongyan Lin2, Yongwen Zhou2
1Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Objective:
To evaluate the efficacy and safety of tubeless hybrid closed-loop (HCL) systems in type 1 diabetes (T1D).
Methods:
We searched Web of Science, PubMed, Scopus, and Embase from inception to April 1st, 2026 for randomized controlled trials (RCTs) comparing tubeless HCL systems with standard care (SC; sensor-augmented pumps [SAP] or multiple daily injections [MDI] + continuous glucose monitoring [CGM]). Primary efficacy outcomes were time in range of 3.9-10.0 mmol/L (TIR) and glycated haemoglobin (HbA1c). Secondary efficacy outcomes included time above range (TAR10.0, TAR13.9), time below range (TBR3.9, TBR3.0), and coefficient of variability (CV). Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA) risks. Random- or fixed-effects models were used as appropriate.
Results:
Four RCTs involving 514 participants were included. The mean age was 32.3 ± 15.7 years, with a mean T1D duration of 14.7 ± 11.1 years, and with mean baseline HbA1c 8.0% ± 1.0%. Three studies compared tubeless HCL with SAP, and one with MDI + CGM. Compared with SC, tubeless HCL improved TIR (MD = 15.31%, 95% CI [7.67%, 22.95%], I 2 = 95%, p < 0.001) and HbA1c (MD = -0.46%, 95% CI [-0.79%, -0.14%], I 2 = 91%, p = 0.005). Lower levels of TAR (TAR10.0, TAR13.9), TBR3.9 and CV were also observed (all p < 0.001) in tubeless HCL group. No significant differences were observed in TBR3.0 (MD = -0.06%, 95% CI [-0.17%, 0.06%], I 2 = 71%, p = 0.35) and insulin dose. DKA and SH events were rare in both groups.
Conclusions:
The available evidence suggests that tubeless HCL systems may improve glycaemic control without increasing insulin dose or short-term safety risks. Head-to-head trials using identical algorithms are needed to isolate form-factor-specific effects.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetic Retinopathy
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Hypoglycemia
Diabetes Mellitus: Type 2 and Gestational